Drug details:
Classification: Phenol ethers; Benzenoids; Organic compounds;

Curated SMILES: CCOC1=C(C=CC(=C1)/C=C(\C(=O)N)/C(=O)N)OCC2=C(C=C(C=C2)Cl)Cl

Evidence for compound's anti-virulence activity:

Clostridium
Related VF: theta-toxin/PFO (Perfringolysin O)
Target: PfoA
Drug effect: Blocks Perfringolysin O (PFO)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PFO-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.

Streptococcus
Related VF: Pneumolysin
Target: Ply
Drug effect: Blocks Pneumolysin (PLY)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PLY-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.